Abstract
Carbapenems (CARBs) are the primary treatment for infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strains. Production of a serine carbapenemase, KPC, is increasing alarmingly in the United States and is probably contributing to CARB resistance rates. We describe the clinical and molecular characteristics of four infections caused by KPC-3 K. pneumoniae strains.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins / biosynthesis*
-
Bacterial Proteins / genetics
-
California
-
Female
-
Humans
-
Klebsiella Infections / microbiology*
-
Klebsiella Infections / pathology*
-
Klebsiella pneumoniae / classification*
-
Klebsiella pneumoniae / enzymology*
-
Klebsiella pneumoniae / isolation & purification
-
Length of Stay
-
Middle Aged
-
beta-Lactamases / biosynthesis*
-
beta-Lactamases / genetics
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
beta-Lactamases
-
beta-lactamase KPC-3, Klebsiella pneumoniae